Forest Laboratories Articles
Major leap in sales at Recordati
14 November 2000
Huge earnings rise at Denmark's Lundbeck
16 August 2000
Forest Labs licenses IBS drug from Rotta
8 August 2000
45% 2nd qtr sales boost for Forest Labs
20 July 2000
Merz' memantine of benefit in Alzheimer's
18 July 2000
Merz + Co and Forest link up for memantine
6 July 2000
Lundbeck 1st-qtr turnover climbs 36%
25 May 2000
Stock Commentary New York
18 May 2000
Forest Labs' S-citalopram
17 May 2000
Merckle and Forest link up for ML3000
14 April 2000
Biovail once-daily diltiazem cleared
8 March 2000
Stock Commentary New York
20 January 2000
Forest Labs applies for listing on NYSE
30 September 1999
Drug majors settle pricing lawsuit in USA
22 February 1999
Correction: Forest Labs' Howard Solomon
7 January 1999
Management Shuffle At Forest Labs
3 December 1998
Goldman Sachs, MSDW Top II's 1998 Analysts List
10 November 1998
Forest Laboratories Postpones US launch of Infasurf.
17 September 1998
CFC-Free Flunisolide
10 September 1998
Many US Companies Go Into The Black For 2nd Qtr
5 August 1998
Citalopram Launched In USA By Forest
22 July 1998
Forest Labs' Celexa "Approvable" In USA
14 May 1998
W-L To Stay Independent As Product Line Improves
30 April 1998
W-L To Stay Independent As Product Line Improves
24 April 1998
Forest And Parke-Davis To Co-Promote Celexa
2 April 1998
Forest Files Two New Applications For Aerobid
16 February 1998
Forest Files for Synapton Approval
20 November 1997
Lundbeck Looks To Continue Strong Growth
6 November 1997
Pharmacia & Upjohn Takes $450 Million Charge
31 October 1997
Forest's Monurol Gains Approval In USA
13 January 1997
Fears Over Tiazac Hit Biovail
23 December 1996
Biovail Shares Soar On Firm's Good News
9 December 1996
Further Profits Warnings From Forest Labs
9 December 1996
First Approval Of Teva's MS Drug Copaxone
25 November 1996
Assessing The Worldwide Market For Generics
28 October 1996
Profits Warning From Forest Labs
16 September 1996
Forest Labs Completes Alzheimer Drug Trials
19 August 1996
Strong Growth For Lundbeck's 1995 Sales And Profits
29 July 1996
US Corporate Results Round-Up
27 May 1996
Forest Licenses US Citalopram Rights
18 March 1996
Extended-Release Diltiazem Available
19 February 1996
Transition For AHP in 1995; Year-End Results
5 February 1996
Forest Laboratories appointment
6 November 1995
Procter & Gamble /Forest Lorcet deal
21 August 1995
FDA Panel Turns Down Monurol NDA
31 July 1995
&Forest's Infasurf Not Approvable, Says FDA
29 May 1995
Infasurf Application To FDA
17 April 1995
Forest Labs' Cervidil Approved In USA
10 April 1995
Forest/Ethical Deal
30 January 1995
Teva Agreement
28 November 1994
Solid 3rd Qtr Growth For Large Pharma Cos
31 October 1994
Torii Licenses UK Product
5 September 1994
Forest Close To Filing For Monurol In USA?
8 August 1994
Strong Gains By US Firms In 2nd Quarter
1 August 1994
OPPORTUNITIES IN SMALL- MID-CAP US DRUG STOCKS
4 July 1994
1ST QUARTER RESULTS VARY FOR US FIRMS
23 May 1994
FOREST PESSARY
22 November 1993
NEW YORK STOCK COMMENT
1 November 1993
FOREST GAINS AF102B LICENSE FOR USA
6 September 1993
SKIN TEST FOR ALZHEIMER'S
16 August 1993
TACRINE CLEARS APPROVAL HURDLE
29 March 1993
RECORD RESULTS FOR FOREST LABS
8 February 1993
STRONG GROWTH STILL TO COME AT FOREST LABS
1 February 1993
FOREST LABS' SYNAPTON TRIALS
7 December 1992
US CHEMICAL/PHARMA COS' POOR PERFORMANCE
9 November 1992
ANALYST'S ESTIMATES OF US THIRD QTR EARNINGS
12 October 1992
&US DRUG COS UNDER-PERFORM IN FIRST QTR
8 June 1992
SMALLER US COMPANIES POST GOOD RESULTS
18 May 1992
GOOD 1991 RESULTS FOR MERCK AND FOREST LABS
3 February 1992
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
